Journal of Clinical Oncology
Articles in this Issue
Supervised home-based exercise in patients with advanced non-small cell lung cancer (NSCLC) on maintenance immune checkpoint inhibitors (ICI).
TPS12143 Background: Lung cancer is the leading cause of cancer-related mortality in the US and results in significant morbidities, including fatigue, dep...
Role of autoimmune reactivity in neurotoxicities (N-Tox) in melanoma patients treated with immune-checkpoint inhibitors (ICI).
2517 Background: N-Tox is a grossly understudied immune-related adverse event (irAE), despite its association with mortality (e.g. encephalitis) and morbi...
Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer.
5603 Background: Cyclin E1 (CCNE1) overexpression or CCNE1 amplification is a predictive indicator of poor prognosis in some endom...
Prognostic impact and racial disparities of chromosome 8q gains in prostate cancer: Insights from integrated molecular profiling.
e17121 Background: Chromosome arm 8q is frequently amplified in prostate cancer, harboring genes that drive tumor progression, therapy resistance, and poo...
Medical racism and physician trust impressions of African-American breast cancer patients enrolled on the navigator-assisted hypofractionation (NAVAH) phase I clinical trial.
e13731 Background: The historical distrust between the African-American community and the medical system, rooted in systemic racism, continues to affect h...
Proteinuria with preserved renal function (PPRF): A retrospective cohort study in newly diagnosed multiple myeloma.
e19559 Background: Myeloma cast nephropathy (MCN) is a negative prognostic marker in newly diagnosed multiple myeloma (NDMM). Patients with NDMM also pres...
Identifying key prognostic indicators in Wilms tumor using machine learning techniques.
4557 Background: Wilms tumor is a rare pediatric malignancy, accounting for 6% of pediatric tumors and primarily affecting the kidneys. Its impact on qual...
MRI-based machine learning model for predicting early relapse in osteosarcoma following neoadjuvant chemotherapy.
11519 Background: Early relapse (ER, ≤ 1 year) in osteosarcoma frequently occurs following neoadjuvant chemotherapy (NAC) and surgical resection. This stu...
Disparities by type of insurance in the journey of cervical cancer care within the context of universal health coverage in Colombia.
e13814 Background: The WHO launched an initiative for cervical cancer elimination, the 4th most common cancer among women worldwide, with 90% of deaths oc...
Preliminary efficacy and safety of TQB2102 in patients with HER2 low-expressing recurrent/metastatic breast cancer: Results from a phase 1b study.
1090 Background: TQB2102 is a novel antibody-drug conjugate (ADC) comprised of a recombinant humanized anti-HER2 bispecific antibody that simultaneously b...
Outcomes of patients with esophageal and gastric carcinomas at a safety-net healthcare system.
e23080 Background: Outcomes for esophageal squamous (ES), esophageal (EA) and gastric adenocarcinomas (G) are poor except for those patients whose cancers...
Diverging paths: Identifying barriers to and increasing accessibility of a survivorship program in a socio-economically diverse community.
e13877 Background: The importance of survivorship programs for enhancing the lives of cancer survivors is well documented in the literature. To maximize e...
Efficacy prediction and prognostic analysis on immunotherapy and TKIs combination treated mRCC by customized tumor-informed ctDNA-MRD.
e16513 Background: Around 20–30% of renal cell carcinoma (RCC) cases are metastatic (mRCC) at diagnosis, and 20–40% of patients develop metastases after n...
Oral oncology adherence application: Real-world pilot results.
e13708 Background: In oncology care, non-adherence can lead to catastrophic and costly outcomes. Patients are highly motivated to follow prescribed treatm...
Comparison of mortality rates in the United States population suffering from Hodgkin's versus non-Hodgkin's lymphoma: A CDC Wonder database study from 1999-2020.
e19068 Background: We conducted this study to compare the mortality rates among United States population suffering from Hodgkin’s and Non-Hodgkin’s lympho...
FFPE RNA-based ddPCR assay: An effective and efficient confirmation for <i>MET</i> exon 14 skipping in NSCLC.
e20643 Background: MET exon14 skipping ( MET ex14sk) mutations occur in 3-5% of non-small cell lung cancer (NSCLC) and...
A phase 1 trial of BTM-3566 in relapsed/refractory mature B cell lymphomas.
TPS7097 Background: Relapsed/refractory (R/R) aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL),...
A prospective, observational phase II clinical study evaluating hepatic artery infusion chemotherapy in combination with HLX10 and HLX04 as first-line treatment for patients with advanced hepatocellular carcinoma.
4098 Background: Advanced hepatocellular carcinoma (HCC) presents limited treatment options. Immunotherapy has emerged as an effective treatment, demonstr...
Comprehensive results of ESG401, a TROP2-targeting ADC: Updated phase 1 analysis in advanced solid tumors.
1044 Background: ESG401 is a novel ADC comprising a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to the Topoisomerase I inhibitor SN-38 via a...
Novel lipid metabolism-related gene signature associated with clinical and immune features in lung adenocarcinoma patients experiencing lymph node metastasis.
e20502 Background: Research has increasingly shown that lipid metabolism contribute to lymph node metastasis and the progression of cancer. This study inv...
AURORA: A single arm, multicentre, phase II clinical trial of atezolizumab immunotherapy for advanced squamous cell carcinoma of the bladder and urinary tract.
4608 Background: Urinary tract squamous cell carcinoma (UTSCC) is a rare disease, comprising approximately 3% of histological subtypes from the bladder an...
Measuring the success of Genentech’s AIR Site Alliance in enrolling diverse patients: A framework.
e23278 Background: Diverse patient representation in clinical trials creates robust data sets that may improve health outcomes for all patients. Roche-Gen...
Analysis of niraparib-induced changes in glucose levels during three-month therapy in normoglycemic patients with ovarian cancer.
e17575 Background: Poly(ADP-ribose) polymerase inhibitors (PARPis) are promising drugs for ovarian cancer (OC) patients, but their safety profile is still...
International phase II randomized placebo-controlled study investigating the combination of YIV-906 plus sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma.
e16244 Background: YIV-906 (formerly PHY906/KD018), inspired by an 1800-year traditional botanical medicine formulation, is being developed under the FDA’...
A phase 1 FIH study of novel oral SERD FWD1802 in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer with or without ESR1 mutations.
e13066 Background: Breast cancer (BC) is the number one cancer in women, and ER+/HER2- is the most prevalent subtype, accounting for about 2/3 of all BCs....